A new drug which is being tested to address colorectal cancer baffled doctors after it registered a surprising 100% success rate in clinical trials.
Dostarlimab, a drug with laboratory produced molecules acting as substitute antibodies in the human bodies, managed to get all 18 participants into remission one year after drug trial.
Doctors conducted physical exams, endoscopies, PET scans and MRI scans, but were still unable to find any trace of cancer in the patients’ bodies.
Dr Luis A. Diaz Jr. of New York’s Memorial Sloan Kettering Cancer Center said that this was the first time it happened in the history of cancer. A paper was published about the findings, which are now making waves in the world of medicine.
Colorectal cancer specialist at the University of California Dr Alan P. Venook, who was not involved with the study, said that complete remission in every patient is unheard of.
The 18 cancer patients involved faced gruelling previous treatments, which included chemotherapy, radiation and invasive surgery which could have resulted in bowel, urinary and sexual dysfunction. The new drug required the patients undergo no further treatment.
This comes as another team of US doctors unveiled their own groundbreaking research which involves a genetically modified cancer killing virus. The drug – Vaxinia – was injected into the first ever human patient and had proved successful in animal trials.
#MaltaDaily